SOFIA, BULGARIA / ACCESS Newswire / March 7, 2025 / The memecoin market has proven that virality and community engagement can turn simple tokens into global sensations. But while most memecoins ...
Shares of BYON opened at $5.53 on Wednesday. The firm has a market capitalization of $294.10 million, a P/E ratio of -0.75 and a beta of 3.91. Beyond has a 12-month low of $4.45 and a 12-month ...
Merck, also known as MSD outside the U.S. and Canada, plans to significantly expand its workforce in India, aiming for around 2,700 employees by the year's end. The company focuses on therapy areas ...
Merck said its “once-in-a-lifetime” drug Keytruda could be subject to price reductions under the Inflation Reduction Act, which would lead to a … ...
Merck is bracing for the years of sales growth from oncology superstar Keytruda to take a sharp turn in 2028—and for more reasons than one. Along with a key U.S. patent expiring at the end of ...
Ivonescimab, the new drug, was found in a trial conducted in China to have bested Keytruda, the blockbuster medication developed by Merck that has raked in more than $130 billion in sales for the ...
Beyond Inc (NYSE:BYON) achieved a gross margin of 23% in Q4, surpassing their target of 21.5%, indicating effective cost management and pricing strategies. The company successfully reduced SG&A ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback